重组抗小鼠NK1.1单抗体(PK136) | Syd Labs PA007525.m2a
体内实验级重组抗小鼠NK1.1单抗（克隆号：PK136，货号：PA007525.m2a），小鼠IgG2a Kappa 是用哺乳动物细胞生产的重组抗体，纯度>95%，适用于体外和体内研究，比如体内NK细胞耗竭(清除)。Syd Labs PA007525.m2a抗小鼠NK1.1抗体不变区为小鼠Mouse IgG2a Kappa (mIgG2a或m2a)，可与重组小鼠IgG2a同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007525.m2a |
|---|---|
| 产品名称 | 重组抗小鼠NK1.1单抗体(PK136) | Syd Labs PA007525.m2a |
| 英文名 | In Vivo Grade Recombinant Anti-mouse NK1.1 Monoclonal Antibody (Clone: PK136), Mouse IgG2a Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | KLRB1C, CD161, Ly-59, NK-RP1, NK-1, Nk-1.2, Nkrp1c, Ly-55c |
| 概述 | Syd Labs 重组抗小鼠NK1.1单克隆抗体(克隆：PK136) 是用哺乳动物细胞生产的重组抗体，可与重组小鼠IgG2a同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | PK136 |
| 同种型 | 小鼠 IgG2a Kappa |
| 特异性 | 体内实验级重组小鼠单克隆抗体 (克隆：PK136) 特异性与小鼠 NK1.1 结合 |
| 抗体形式 | 0.2 μM过滤溶液，pH 7.4，不含稳定剂或防腐剂 |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗小鼠NK1.1单克隆抗体（克隆号PK136），小鼠IgG2a Kappa用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 自收到之日起 1 个月，保存在2 至 8°C。 自收到之日起12个月，保存在-20 至 -70°C。 |
| 注意事项 | PA007525.m2a Syd Labs：抗小鼠NK1.1单克隆抗体是用哺乳动物细胞生产的，可与重组小鼠IgG2a同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | ELISA、中和、功能测定，如生物分析PK和ADA测定，以及用于研究受小鼠NK1.1蛋白影响的生物途径的测定 |
文献
PA007525.m2a: Syd Labs体内实验级重组抗小鼠NK1.1单克隆抗体（克隆号PK136），小鼠IgG2a Kappa（In Vivo Grade Recombinant Anti-mouse NK1.1 Monoclonal Antibody (Clone: PK136), Mouse IgG2a Kappa）
体内实验级重组抗小鼠NK1.1单克隆抗体（克隆号：PK136，小鼠IgG2a Kappa）是自然杀伤细胞（NK细胞）和NKT细胞功能研究中的金标准试剂。NK1.1（又称 CD161c 或 Klrb1c）是一种表达于特定品系小鼠（如 C57BL/6、NZB 等）NK 细胞及 NKT 细胞表面的 C 型凝集素样受体，在介导细胞毒性与细胞因子产生中发挥关键作用。克隆号 PK136 单克隆抗体能特异性识别并结合小鼠 NK1.1 分子，广泛应用于 NK 细胞表型鉴定、流式细胞术（FC）、免疫组化及体内外免疫调控实验。该抗体采用重组表达技术构建为小鼠 IgG2a Kappa 格式，极大地提升了批间一致性与生产稳定性，同时有效降低了动物模型中的异源免疫原性。
该体内实验级重组抗小鼠NK1.1单抗（PK136，小鼠IgG2a）由哺乳动物（CHO）细胞系统重组表达生产，具备超高纯度与超低内毒素水平（<1 EU/mg），无叠氮化钠及无载体蛋白，专为严苛的体内（in vivo）NK细胞耗竭与功能阻断实验设计。借助小鼠 IgG2a 格式与 Fcγ 受体的高亲和力结合，重组抗小鼠 NK1.1 抗体（克隆号 PK136）能高效介导抗体依赖性细胞毒作用（ADCC），在体内快速且彻底地清除 NK 细胞。在肿瘤免疫监视、病毒感染机理及移植排斥反应研究中，该重组单抗是高效的靶向清除工具，配套使用重组小鼠 IgG2a 同型对照抗体可确保科研数据的严谨性与高可重复性。
抗小鼠 NK1.1 单克隆抗体（克隆号：PK136）参考文献：
1. Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy.
Ghasemi, R., et al. Nat Commun. 2016 Sep 21;7:12878. PMID: 27650575
“Data were acquired flow cytometrically and is representative of three separate experiments with MFI comparison of PE-labelled constructs on NK cells (viable, NK1.1+, CD3-, CD19-). … NK cells were defined as viable, NK1.1+CD3-CD19-. … For NK cell depletion, mice were treated with anti-NK1.1 antibody (clone PK136) or mouse IgG isotype control (both from BioXcell) at 500 µg day -2, 250 µg day -1 and 250 µg weekly for the duration of the experiment. … Data representative of 5 mice per group for both NK1.1 depleted and NKG2D deficient mice. (f) LLC tumour growth in C57BL/6Rag1-/- mice. …Increased efficacy of OMCP-mutIL-2 immunotherapy disappears in NKG2D-/- or NK1.1 depleted mice.”
2. NLRC5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions.
Ludigs, K., et al. Nat Commun. 2016 Feb 10;7:10554. PMID: 26861112
“(b) H2-K and H2-D expression, depicted as mean fluorescence intensity (MFI), was analysed by flow cytometry on splenic CD4+ and CD8+ T cells (CD3+CD4+ and CD3+ CD8+, respectively), NK cells (NK1.1+CD3-), B cells (CD19+) and DCs (CD11c high) from Nlrc5 fl/fl, Nlrc5-/- and B2m-/- mice. … In some mice, NK cells were depleted by intraperitoneal injection of 200 µg of α-NK1.1 antibody (PK-136, purchased from BioXcell) 1-2 days before cell transfer. … NK cells were isolated using the NK-cell-negative selection kit from StemCell Technologies (Grenoble, France), according to the manufacturer’s recommendations. … NK1.1 (PK-136, 1:100), NKp46 (29A1.4, 1:100), Qa2 (69H1-9-9, 1:200), Rae1γ (RD-41, 1:75) (all from eBioscience), H2-Ld (28-14-8, 1:200), Ly49H (3D10, 1:100) and Ly49C/I (5E6, 1:100; from BioLegend). … In some mice, NK cells were depleted as described above.”
Guo, Z., et al. PLoS One. 2014 Feb 27;9(2):e89350. PMID: 24586709
“Therapeutic anti-OX40 (Clone OX-86; Catalog#:BE0031), anti-PD-1 (Clone RMT3-23; Catalog#BE0115), anti-CD4 (Clone GK1.5; Catalog#:BE0003-1), anti-CD8 (Clone 2.43; Catalog#:BE0061), anti-NK1.1 (Clone PK136; Catalog#:BE0036) and control rat IgG2a mAb (Clone 2A3; Catalog#:BE0089) were purchased from BioXcell (West Lebanon, NH). … For depletion of lymphocyte subsets, mice were injected i.p. with 500 µg of mAb against CD8, CD4, or NK1.1, 1 day before and two days after tumor challenge, followed by injection of 200 µg every 5 days throughout the experiment. … Lymphocyte subset depletion experiments demonstrated that tumor protection by anti-PD-1/OX40 mAbs was dependent on the CD4+ and CD8+ T cells as removal of CD4+ or CD8+ T cells but not NK cells completely abrogated the antitumor effect conferred by anti-PD-1/OX40 mAb treatment. … Mice (5 mice per group) injected i.p. with 1×10^6 ID8 cells 10 day earlier were injected thrice at 4 days interval with 200 µg of control, single or combined anti-PD-1/OX40 mAb. Three or seven days later, peritoneal lavages from treated mice were analyzed by flow cytometry for the composition of various immune subsets. … The percentages of CD4+FoxP3- T cells, CD8+ T cells, CD4+FoxP3+ Treg and CD11b+GR-1+ MDSC in CD45+ peritoneal immune cells are shown in A, B, C and D respectively with each dot representing data from each mouse.”
Walsh, K. B., et al. J Virol. 2014 Jun;88(11):6281-93. PMID: 24672024
“For cell depletion experiments, 250 µg of anti-NK1.1 (PK136; Bioxcell) and/or 500 µg of anti-CD8 (53-6.72; Bioxcell) antibodies were administered i.p. to mice 1 day before and 1 day after infection. … Isolated cells were stained with antibodies raised against murine CD11b (M1/70), CD11c (HL3), Ly6C (HK1.4), Ly6G (1A8), F480 (BM8), NK1.1 (PK136), CD3e (145-2C11), CD4 (L3T4), CD8a (53-6.7), CD90.2 (53-2.1), B220 (RA3-6B2), CD103 (M290), CD69 (HI.2F3), CD44 (IM7), CD40 (MH40-3), CD80 (16-10A1), CD86 (GL1), PD-L1 (MIH5), H-2Kb (AF6-88.5), and I-A/I-E (M5/114.15.2). … Cytokine production by NK cells and CD8+ T cells within the lung on day 5 after PVM infection was determined by 5 h of incubation of single-cell suspensions in culture medium (RPMI with 10% fetal bovine serum [FBS], 2 mM l-glutamine, and 100 U [each] of penicillin-streptomycin) with 4 µg/ml brefeldin A (Sigma, St. Louis, MO, USA) in the absence of exogenous stimulation. …NK cells and CD8+ T cells were stained for surface antigen (NK1.1+ CD3- and CD8+ CD90.2+, respectively), fixed, permeabilized with 2% saponin, and then stained for intracellular proteins with fluorescently labeled antibodies specific for murine IFN-γ (XMG1.2) and TNF-α (MP6-XT22). … In flow cytometric analysis, lung infiltrates of mice given RP-002 showed significantly fewer CD8+ T cells and NK cells than vehicle on day 5 postinfection.”
Ellermeier, J., et al. Cancer Res. 2013 Mar 15;73(6):1709-20. PMID: 23338611
“Where indicated, CD8+ T cells or NK cells were depleted one day before RNA treatment with 500 µg of anti-CD8 monoclonal antibody (mAb; clone YTS 169.4) or anti-NK1.1 mAb (clone PK136; BioXCell). … Depletion efficacy was assessed by fluorescence-activated cell sorting (FACS) analysis of peripheral blood and was more than 98% after 24 hours. … Therapeutic efficacy was dependent on CD8+ T cells, whereas natural killer cells were dispensable. … Intravenous injection of ppp-TGF-β reduced systemic and tumor-associated TGF-β levels. … In addition, it induced high levels of type I IFN and CXCL10 in serum and tumor tissue, systemic immune cell activation, and profound tumor cell apoptosis in vivo.”
6. Macrophage and T cell produced IL-10 promotes viral chronicity.
Richter, K., et al. PLoS Pathog. 2013;9(11):e1003735. PMID: 24244162
“Depletion of NK-like cells was performed by i.p. administration of 300 µg α-NK1.1 (PK136, BioXCell) on days -3 and -1 (depletion efficacy of 96% while the percentage of CD3+ cells was not affected). … NK cells constituted 0.96±0.23% of the splenocytes on day 2 and 1.81±0.13% on day 5 post infection while NKT cells accounted for 0.11±0.05% on day 2 and 0.2±0.03% on day 5. … Depletion of neutrophils, CD4+ or CD8+ T cells, CD25+ T cells and B cells did not lead to a decrease in the overall IL-10 mRNA levels. …Unexpectedly, depletion of NK-like cells did not result in overall decreased IL-10 mRNA levels despite the high IL-10 mRNA expression level in purified cells. … NK cells were isolated from splenocytes on day 7 after i.p. infection with 5×10^4 pfu MCMV Smith by magnetic negative selection of CD3+ and CD19+ cells and subsequent FACS sorting of CD3- NK1.1+ cells.”